HFY-4A is a HDAC inhibitor. HFY-4A inhibits breast cancer cell proliferation, migration, and invasion, and induces cell apoptosis. HFY-4A induces immunogenic cell death (ICD). HFY-4A inhibits tumor growth in breast cancer xenograft mouse models[1].
References:
[1]. Yin Y, et al. The HDAC inhibitor HFY-4A improves TUSC2 transcription to induce immunogenic cell death in breast cancer. Toxicol Appl Pharmacol. 2023 Nov 1;478:116698.